Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania.
PMID: 35107140
2022
The Journal of antimicrobial chemotherapy
Discussion: The most plausible explanations for the occurrence of T215Y, D67N, M41L, K219K/Q and K70R TAMs among patients with tenofovir disoproxil fumarate-based ART regimen failure are that these TAMs were transmitted drug resistance RAMs (TDR-RAMs) or were selected by exposure to undisclosed thymidine analogue-based regimens.
Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria.
PMID: 34741609
2022
The Journal of antimicrobial chemotherapy
Result: Sixteen participants had all of the TAM 1 pathway mutations (M41L, L210W and T215Y), 11 had all of the TAM 2 pathway mutations (D67N, K70R, T215F and K219Q/E) and four had the mutations for both pathways.
Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.
PMID: 34694878
2022
Antimicrobial agents and chemotherapy
Table: K219Q
Rising rates of recent preexposure prophylaxis exposure among men having sex with men newly diagnosed with HIV: antiviral resistance patterns and treatment outcomes.
Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
PMID: 34897227
2022
Journal of acquired immune deficiency syndromes (1999)
Table: K219Q
High HIV-1 Virological Failure and Drug Resistance among Adult Patients Receiving First-Line ART for At least 12 Months at a Decentralized Urban HIV Clinic Setting in Senegal before the Test-and-Treat.
Result: Thymidine analog mutations (TAM) were detected in 35.4% of the individuals [17.1% (14/82) TAM-1 (including M41L, L210W, and T215Y) and 20.7% (17/82) TAM-2 (including D67N, K70R, T215F, and K219Q/E)].
Transmitted HIV drug resistance and subtype patterns among blood donors in Poland.
Result: Transmitted drug resistance mutations (tDRM), based on WHO mutation list, were observed in one (0.6%) protease (L54M mutation), 6 (3.8%) NRTI (mutations in the codon positions: M41L, D67N, T215S/V, K219Q) and two (1.1%) (both E138K mutations) integrase sequences (supplemental table 2).
Discussion: As expected the most common NRTI DRMs were thymidine analog mutations, namely M41L, D67N, T215S/V, K219Q, associated with high levels of resistance to zidovudine, but also affect the abaca
Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance.
Method: Thymidine-analog mutations were defined as the NRTI-SDRMs M41L, D67N/G/E, K70R, L210W, T215Y/F/S/C/D/E/I/V, and K219Q/E/N/R.
Transmitted HIV-1 drug resistance in a large international cohort using next-generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study.
Abstract: Using the 2% detection threshold, individual DRMs with the highest prevalence were: PI M46IL (5.5%), RT K103NS (3.5%), RT G190ASE (3.1%), T215ISCDVEN (2.5%), RT M41L (2.2%), RT
Discussion: The most commonly detected NRTI DRMs, K219QENR and M184VI, occurred predominately as minor variants while the majority of patients with T215 revertants had the mutation in > 80% of the quasispecies.
HIV mutation literature information.
PMID: 
2022
The Journal of antimicrobial chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT